GSK Trading Volume Surges 218.44% to 245th Position Despite Stock Price Decline

On May 6, 2025, GSK's trading volume reached 3.50 billion, marking a significant 218.44% increase from the previous day. This surge placed GSK at the 245th position in terms of trading volume for the day. However, GSK's stock price experienced a decline of 3.47%, marking the second consecutive day of losses, with a total decrease of 4.02% over the past two days.

One of the key factors contributing to the recent volatility in GSK's stock price is the scrutiny faced by the recommendations for RSV vaccines produced by Pfizer and GSK. A recommendation has been proposed to expand the eligibility for these vaccines to high-risk adults aged 50-59, lowering the current threshold age of at least 60. This development has drawn attention from Robert F. Kennedy Jr.'s aide, who has questioned the recommendations, adding to the uncertainty surrounding the vaccines' market potential.

Additionally, the appointment of Dr. Vinay Prasad to lead the FDA's division regulating biologics and vaccines has brought further attention to the regulatory landscape for vaccine manufacturers. Prasad's role will involve overseeing the safety and efficacy of vaccines, including those produced by GSK, which could impact the company's future product approvals and market strategies.

Despite these challenges, GSK continues to focus on its vaccine portfolio, which includes the RSV vaccine. The company's efforts to expand the eligibility for this vaccine and navigate the regulatory environment will be crucial in determining its future performance. Investors will be closely monitoring these developments as they assess the potential impact on GSK's stock price.